Special Issue "Adhesion and Integrins"

Quicklinks

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (30 October 2012)

Special Issue Editor

Guest Editor
Prof. Dr. Kairbaan Hodivala-Dilke

The Adhesion and Angiogenesis Laboratory, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London
E-Mail
Interests: Adhesion and Integrins, Tumour Angiogenesis, Cancer Cell Biology, Metastasis and Invasion and Breast Cancer

Special Issue Information

Dear Colleagues,

Cancer initiation, growth, progression and metastasis are all stages of the disease that involve changes in both cell-cell and cell-matrix adhesion.  Such changes occur not only the tumour cell compartment but also in the stromal compartment, with changes in the adhesive capacity of immune cells, tumour associated fibroblasts, endothelial cells and so on. It is increasing evident that blockade of such adhesion molecules may have therapeutic value. The special issue of Cancers on ‘Adhesion and Integrins’ will include original research articles and review articles on the influence of adhesion molecules in cancer development and how we can exploit such changes for therapeutic advance.

Prof. Kairbaan Hodivala-Dilke
Guest Editor

Keywords

  • Integrins
  • Cadherins
  • Metastasis
  • Invasion
  • Angiogenesis
  • Stroma
  • Cancer
  • Immune infiltration

Published Papers (2 papers)

View options order results:
result details:
Displaying articles 1-2
Export citation of selected articles as:

Review

Open AccessReview Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors
Cancers 2013, 5(1), 27-47; doi:10.3390/cancers5010027
Received: 5 December 2012 / Revised: 9 January 2013 / Accepted: 11 January 2013 / Published: 15 January 2013
Cited by 34 | PDF Full-text (234 KB) | HTML Full-text | XML Full-text
Abstract
Integrins are transmembrane heterodimeric proteins sensing the cell microenvironment and modulating numerous signalling pathways. Changes in integrin expression between normal and tumoral cells support involvement of specific integrins in tumor progression and aggressiveness. This review highlights the current knowledge about α5β1 integrin, also
[...] Read more.
Integrins are transmembrane heterodimeric proteins sensing the cell microenvironment and modulating numerous signalling pathways. Changes in integrin expression between normal and tumoral cells support involvement of specific integrins in tumor progression and aggressiveness. This review highlights the current knowledge about α5β1 integrin, also called the fibronectin receptor, in solid tumors. We summarize data showing that α5β1 integrin is a pertinent therapeutic target expressed by tumoral neovessels and tumoral cells. Although mainly evaluated in preclinical models, α5β1 integrin merits interest in particular in colon, breast, ovarian, lung and brain tumors where its overexpression is associated with a poor prognosis for patients. Specific α5β1 integrin antagonists will be listed that may represent new potential therapeutic agents to fight defined subpopulations of particularly aggressive tumors. Full article
(This article belongs to the Special Issue Adhesion and Integrins)
Open AccessReview RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis
Cancers 2012, 4(4), 1106-1145; doi:10.3390/cancers4041106
Received: 23 August 2012 / Revised: 9 October 2012 / Accepted: 22 October 2012 / Published: 26 October 2012
Cited by 17 | PDF Full-text (714 KB) | HTML Full-text | XML Full-text
Abstract
Prostate cancer is the third leading cause of male cancer deaths in the developed world. The current lack of highly specific detection methods and efficient therapeutic agents for advanced disease have been identified as problems requiring further research. The integrins play a vital
[...] Read more.
Prostate cancer is the third leading cause of male cancer deaths in the developed world. The current lack of highly specific detection methods and efficient therapeutic agents for advanced disease have been identified as problems requiring further research. The integrins play a vital role in the cross-talk between the cell and extracellular matrix, enhancing the growth, migration, invasion and metastasis of cancer cells. Progression and metastasis of prostate adenocarcinoma is strongly associated with changes in integrin expression, notably abnormal expression and activation of the β3 integrins in tumour cells, which promotes haematogenous spread and tumour growth in bone. As such, influencing integrin cell expression and function using targeted therapeutics represents a potential treatment for bone metastasis, the most common and debilitating complication of advanced prostate cancer. In this review, we highlight the multiple ways in which RGD-binding integrins contribute to prostate cancer progression and metastasis, and identify the rationale for development of multi-integrin antagonists targeting the RGD-binding subfamily as molecularly targeted agents for its treatment. Full article
(This article belongs to the Special Issue Adhesion and Integrins)

Journal Contact

MDPI AG
Cancers Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
cancers@mdpi.com
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18
Editorial Board
Contact Details Submit to Cancers
Back to Top